{
  "data": {
    "id": "stat_HFHZXJPD95DADX4EABJNWH1JSZ",
    "url": "https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ",
    "indicator": {
      "slug": "ctgov-autoimmune-trial-starts",
      "name": "Autoimmune cell therapy and T-cell engager trial starts",
      "definition": "Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "period": {
      "start": "2022-01-01",
      "end": "2022-12-31",
      "type": "year"
    },
    "value": 3,
    "value_text": "3 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.",
      "quote": "{\"totalCount\":3,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=%22CAR-T%22%20OR%20%22CAR%20T%22%20OR%20%22chimeric%20antigen%20receptor%22%20OR%20CAR-NK%20OR%20%22T%20cell%20engager%22%20OR%20blinatumomab%20OR%20teclistamab%20OR%20mosunetuzumab%20OR%20imvotamab&query.cond=lupus%20OR%20%22systemic%20sclerosis%22%20OR%20myasthenia%20OR%20%22multiple%20sclerosis%22%20OR%20myositis%20OR%20%22rheumatoid%20arthritis%22%20OR%20vasculitis%20OR%20autoimmune%20OR%20neuromyelitis%20OR%20Sjogren%20OR%20%22immune%20thrombocytopenia%22%20OR%20nephropathy%20OR%20pemphigus&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20NOT%20%28AREA%5BCondition%5Dcancer%20OR%20AREA%5BCondition%5Dtumor%20OR%20AREA%5BCondition%5Dneoplasm%20OR%20AREA%5BCondition%5Dcarcinoma%20OR%20AREA%5BCondition%5Dlymphoma%20OR%20AREA%5BCondition%5Dleukemia%20OR%20AREA%5BCondition%5Dmyeloma%20OR%20AREA%5BCondition%5Dmalignancy%29%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ",
      "bibtex": "@misc{clinicaltrialsgo2022ctgovwh1jsz,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n  year         = {2022},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_HFHZXJPD95DADX4EABJNWH1JSZ},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=\\%22CAR-T\\%22\\%20OR\\%20\\%22CAR\\%20T\\%22\\%20OR\\%20\\%22chimeric\\%20antigen\\%20receptor\\%22\\%20OR\\%20CAR-NK\\%20OR\\%20\\%22T\\%20cell\\%20engager\\%22\\%20OR\\%20blinatumomab\\%20OR\\%20teclistamab\\%20OR\\%20mosunetuzumab\\%20OR\\%20imvotamab\\&query.cond=lupus\\%20OR\\%20\\%22systemic\\%20sclerosis\\%22\\%20OR\\%20myasthenia\\%20OR\\%20\\%22multiple\\%20sclerosis\\%22\\%20OR\\%20myositis\\%20OR\\%20\\%22rheumatoid\\%20arthritis\\%22\\%20OR\\%20vasculitis\\%20OR\\%20autoimmune\\%20OR\\%20neuromyelitis\\%20OR\\%20Sjogren\\%20OR\\%20\\%22immune\\%20thrombocytopenia\\%22\\%20OR\\%20nephropathy\\%20OR\\%20pemphigus\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20NOT\\%20\\%28AREA\\%5BCondition\\%5Dcancer\\%20OR\\%20AREA\\%5BCondition\\%5Dtumor\\%20OR\\%20AREA\\%5BCondition\\%5Dneoplasm\\%20OR\\%20AREA\\%5BCondition\\%5Dcarcinoma\\%20OR\\%20AREA\\%5BCondition\\%5Dlymphoma\\%20OR\\%20AREA\\%5BCondition\\%5Dleukemia\\%20OR\\%20AREA\\%5BCondition\\%5Dmyeloma\\%20OR\\%20AREA\\%5BCondition\\%5Dmalignancy\\%29\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}